The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Recent Progresses in Phototherapy‐Synergized Cancer Immunotherapy
Open accessAbstract
Cancer immunotherapy has recently gained much attention in the search of cancer cure due to its ability to “train” the immune system in seeking out and removing residual tumor cells. However, relying on cancer immunotherapy alone may fail to ablate primary tumors. Phototherapy is a promising modality that offers an elegant solution to eradicate tumors through the simple application of light irradiation and meanwhile triggers immune responses by immunogenic cell death to enhance antitumor immunity. Uniting phototherapy with cancer immunotherapy has been found to achieve synergistic outcomes, promote cancer regression, and even attain immunologic memory. This review summarizes the recent studies on utilizing phototherapy and immunotherapy combinatorial approaches to treat cancer. A variety of nanoplatforms have been investigated in combination with immunoadjuvants and immune checkpoint blockades such as CTLA4 and PD‐L1 pathways. Higher levels of proinflammatory cytokines, improved migration of dendritic cells, and an increased ratio of tumor‐infiltrating cytotoxic T cells against regulatory T cells are revealed in many studies, offering a glimpse into the mechanistic principles. Future advancements targeting different cancer checkpoints that could offer better immunosuppression coupled with other phototherapeutic strategies remain to be explored in accomplishing complete elimination of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
A clearer vision for in vivo imaging
Weissleder, R. (2001) · Nature Biotechnology · doi:10.1038/86684 · Cited by 3,839
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Second window for in vivo imaging
Smith, A. M., Mancini, M. C., & Nie, S. (2009) · Nature Nanotechnology · doi:10.1038/nnano.2009.326 · Cited by 2,848
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Cited by
Clinical development and potential of photothermal and photodynamic therapies for cancer
Li, X., Lovell, J. F., Yoon, J., & Chen, X. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0410-2 · Cited by 3,456
Second near-infrared photothermal materials for combinational nanotheranostics
Xu, C., & Pu, K. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00664e · Cited by 941
Self-citationImmune Cell Membrane‐Coated Biomimetic Nanoparticles for Targeted Cancer Therapy
Oroojalian, F., Beygi, M., Baradaran, B., Mokhtarzadeh, A., & Shahbazi, M. (2021) · Small · doi:10.1002/smll.202006484 · Cited by 528
Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 522
Chen, C., Ni, X., Jia, S., Liang, Y., Wu, X., Kong, D., & Ding, D. (2019) · Advanced Materials · doi:10.1002/adma.201904914 · Cited by 503
Metadata
- Authors
- Ng, C. W., Li, J., & Pu, K.
- Venue
- Advanced Functional Materials
- Publisher
- Wiley
- Published
- 2018-09-20
- Volume
- 28
- Issue
- 46
- ISSN
- 1616-301X (ISSN-L)
- 1616-3028
- OpenAlex
- W2890587360
- Cited by
- 349
- References
- 14
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Progresses in Phototherapy‐Synergized Cancer Immunotherapy. https://app.cochat.ai/papers/10.1002/adfm.201804688
- The paper
- Ng, C. W., Li, J., & Pu, K. (2018). Recent Progresses in Phototherapy‐Synergized Cancer Immunotherapy. Advanced Functional Materials. https://doi.org/10.1002/adfm.201804688
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
